|Bid||N/A x N/A|
|Ask||N/A x N/A|
|Day's Range||N/A - N/A|
|52 Week Range||undefined - undefined|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
NEW YORK, NY / ACCESSWIRE / May 2, 2017 / JGR Capital Partners, a leading equity research and digital investor relations firm, has announced it has initiated coverage on KaloBios (OTC PINK: KBIO) with ...
Rare Disease Week was rapidly followed by more proposals to gut the ACA healthcare and the FDA, immigration and travel bans which will decimate research and healthcare (as well as being needless and cruel), and reduce research budgets. How does this help patients?
BRISBANE, CA / ACCESSWIRE / February 13, 2017 / KaloBios Pharmaceuticals, Inc. (OTC PINK: KBIO), a biopharmaceutical company focused on advancing medicines for patients with neglected and rare diseases, ...